John Niederhuber - 03 Aug 2016 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role: Director
Signature: SoYoung Kwon, Attorney-in-Fact
Issuer symbol: APVO
Transactions as of: 03 Aug 2016
Net transactions value: +$650
Form type: 4
Filing time: 03 Jun 2022, 15:06:18 UTC
Next filing: 02 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APVO	Common Stock	Purchase	$650	+714	+89%	$0.9100^*	1,516	14 Jun 2019	Direct	F2
transaction	APVO	Common Stock	Options Exercise		+298	+20%		1,814	01 Jun 2022	Direct	F3
holding	APVO	Common Stock						802	03 Aug 2016	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APVO	Restricted Stock Unit	Options Exercise	$0	-298	-33%	$0.000000	595	01 Jun 2022	Common Stock	298		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares received in a pro rata distribution by Emergent BioSolutions Inc. ("Emergent") as a result of the spin-off of the Issuer from Emergent, effective August 1, 2016, and adjusted to reflect a 1-for-14 reverse stock split of the Issuer's common stock effective as of March 26, 2020.
F2	Reflects a 1-for-14 reverse stock split of the Issuer's common stock effective as of March 26, 2020.
F3	Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F4	On June 1, 2021, the reporting person was granted 893 RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022.